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Non-invasive ventilation (NIV) is beneficial for respiratory failure in motor neurone disease 
(MND) but some patients may wish to stop the intervention. Guidance from the National 
Institute for Health and Care Excellence recommends that research is needed on NIV 
withdrawal. There is little in the literature focusing on the issues doctors face when 
withdrawing NIV in this group. 
 
Aim  
To identify issues and challenges that palliative medicine doctors encounter in relation to 
the withdrawal of NIV in MND patients.  
 
Method  
An electronic questionnaire was sent to members of the Association of Palliative Medicine 
of Great Britain and Ireland. Participants rated how practically, emotionally and ethically 
challenging they found the process of NIV withdrawal. 
 
Results  
76 doctors responding had been directly involved in withdrawal of NIV at the request of a 
patient with MND. A high percentage rated the practical, ethical and emotional challenges 
as 7 or more on a 0 W10 scale. Thematic analysis of the free text revealed some common 
difficulties. Lack of guidance on practical aspects of withdrawal, poor advance care 
planning and the need to support all involved to prevent conflict were recurrent themes. 
Statements relating to the emotional burden were diverse but suggest many palliative care 
doctors feel significant personal impact. 
 
Conclusions  
The withdrawal of NIV in patients with MND appears to pose considerable challenges to 
palliative medicine doctors; emotionally, practically and to a lesser extent ethically. 
Development of guidelines and a clear ethical statement of conduct may help but 





















Motor neurone disease (MND) is a progressive neurological condition which primarily affects 
motor neurones leading to skeletal muscle weakness. Respiratory muscle weakness leads to 
fatigue, breathlessness, hypoxia, hypercapnia, morning headaches, poor sleep, anorexia, anxiety 
and the risk of infection due to poor cough clearance of secretions. Most deaths in MND are due 
to respiratory failure.  NIV can improve both symptoms and sur- vival,1 2 and recent UK guidance 
from the National Institute for Health and Care Excellence (NICE) supports its use.3 
 
Some, but by no means all, patients with respiratory failure due to MND choose to use NIV. 
Little is known about patient decision making but it would seem that many patients make this 
choice to improve their quality of life. Other work has suggested that the disease itself takes 
away any sense of autonomy in decision making.4 Undoubtedly, NIV has many benefits for 
patients.5 6 Neurological deterioration is however relentless for patients despite NIV and 
patients may eventually reach a point at which they cannot move or communicate. Many also 
develop dementia and cognitive change, primarily frontal lobe dysfunction, which affects their 
executive functioning and ability to make decisions. The ability to control discontinuation of 
ventilation may be a crucial factor for the patient making the decision about starting the 
treatment.7  
 
One study found that half of the users of respiratory support discontinued it well before dying 
from their MND.8 Additional information should shortly be available from two longitudinal 
cohort studies of patients using NIV which have recently been undertaken in the UK (McDermott 
and Young, personal communication 2012). There is little other literature that helps us 
understand what proportion of patients become dependent on NIV (ie, get severely breathless 
without it within a very short space of time) and utilise it almost 24/7, but retrospective studies 
suggests this may be so for around 50% of patients who use NIV. NIV can very effectively support 
ventilation, often for many months, but the majority of patients using NIV 24/7 in the UK appear 
to die while still using it. In the UK, very few people are on tracheostomy delivered ventilation. 
 
Some patients who are dependent on NIV will wish it to be stopped because they can no longer 
tolerate it or because of deterioration in other factors in their quality of life. Some will have 
made a written statement with respect to withdrawal in advance of their losing the ability to 
communicate (or altered capacity).9 If properly written and witnessed, an advance decision to 
refuse treatment (ADRT) iƐ ůĞŐĂůůǇďŝŶĚŝŶŐĂŶĚĐůĞĂƌůǇ ƐƚĂƚĞƐ ƚŚĞƉĂƚŝĞŶƚ ?ƐǁŝƐŚĞƐ ?10 Interviews 
with patients on assisted ventilation in the USA (mostly receiving this via tracheostomy) found 
that while most patients wanted to issue a direction in advance about circumstances in which 
they would wish to stop assisted ventilation, few had had the opportunity to do so.11 Whitehead 
et  al12  explored end of life decision making with patients and with bereaved carers in Preston, 
UK, and identified a need for more information and shared decision making, but there is little 
other literature exploring this area in the UK. 
 
The recent UK NICE guidance identifies the lack of evidence on providing information to family 
and patients using NIV in relation to end of life care and was unable to draw on any evidence 
pertaining to the timing and content of end of life care discussions with patients and family.3 The 
guidance does suggest that discussion of withdrawal should take place before or as NIV is 
started, and discussions regarding end of life care should be instigated if the patient or family 




Withdrawal of NIV 
 
The NICE guidance also states that more research is needed on the withdrawal of NIV, 
identifying the lack of any clarity in the most effective and acceptable method of withdrawal 
and how this process should be facilitated and managed. Specifically, NICE suggests 
interviewing the professionals involved in such events as a focus of research (see NICE Clinical 
Guideline 1053, p96). 
 
For those patients who use NIV most of the time, removal of NIV will usually be followed by 
death within hours, although anecdotally this has proved surprisingly variable. Removal of NIV 
usually leads to a rapid onset of distressing symptoms and medication is needed to manage the 
physical distress that may result from NIV withdrawal. There is a very small literature discussing 
the clinical and practical aspects of withdrawal of NIV in MND,3  13 W18  and  some  on  the 
withdrawal of ventilation for other conscious patients.19 W22 Other than a recent BBC radio pro- 
gramme23 and two case studies,21 24 there is no work which has looked at what can be learned 
from the experiences of professionals or close family carers. 
 
Withdrawing NIV support from an MND patient whose life depends on it is a rare event. 
There are no statistics available but our experiences suggests at most currently 1 W2 
people/million population per year in the UK or around 0.5 W1%  of  patients  with  MND. This 
could increase with the increased awareness of the use of NIV following the NICE guidance 
and if trials of diaphragmatic pacing show benefit. It is clearly important to learn as much as 
possible from those that have experience of managing such patients in order to inform 




Impact of NIV withdrawal on health professionals  
 
Experience tells us that all concerned (patient, family and professional caregivers) find stopping 
something that has been keeping a person alive a difficult situation. However, there is minimal 
research about the experience and concerns of any party. 
 
There has been an exploration of the ethical context of withdrawal of NIV,13 14 21 25  and  this  
emphasises the stressful nature of this area of clinical care and how differences in opinion and 
belief, despite a ƵŶŝĨŽƌŵůĞŐĂůĐŽŶƚĞǆƚ ?ĐĂŶŝŶĨůƵĞŶĐĞĂĚŽĐƚŽƌ ?ƐƉƌĂĐƚŝĐĞĂŶĚůĞǀĞůŽĨĚŝƐƚƌĞƐƐ ?
The literature has not explored the actual experiences of doctors (or indeed of patients, their 
families or other health professionals) 
 
Withdrawal of life sustaining treatment from insentient patients who are dying from organ 
failure or brain injury (not MND) in intensive care units indicates emotional impact on 
professional team members,26 and physicians consider mechanical ventilation the most difficult 
treatment to withdraw.27 In the context of MND where patients may remain able to hear, see, 
think and feel normally, but may not be able to communicate, the impact on their professionals 
could be expected to be even greater. 
 
Gannon24 noted a high level of distress for staff and a change in their professional behaviour in 
a hospice setting where they considered accepting a patient with MND for NIV withdrawal. He 
postulates that withdrawal of a ventilator generates more concern than withdrawing fluids, for 





Clinch and Le21 have recently described withdrawal of mechanical ventilation at home in a 
ĐŽŶƐĐŝŽƵƐƉĂƚŝĞŶƚǁŝƚŚŝƌƌĞǀĞƌƐŝďůĞƌĞƐƉŝƌĂƚŽƌǇĨĂŝůƵƌĞ ?ĨĞĂƚƵƌĞŽĨƚŚŝƐĐĂƐĞƐƚƵĚǇǁĂƐ ?ƚŚĞ
attitudinal barrier  encountered from the local domiciliary palliative care service, who were not 
prepared to be involved directly with the withdrawal of ventilation itself, although they were 
fully supportive of care of the patient and his family once the procedure had been ĐŽŵƉůĞƚĞĚ ? ? 
 
A recent BBC radio 4 Inside the ethics committee broadcast further illustrated the issues that 
can arise through the retelling of the stories of two patients.23 Issues were raised as to the role 
of the doctor, the points of uncertainty and the conflicts that may arise in a team when 
individuals have differing ethical understanding and values. 
 
The Leicestershire guidelines28 acknowledge that, in view of the complex emotional impact of 
withdrawing NIV,  ?ĚĞďƌŝĞĨŝŶŐĂŶĚƐupport should be available to ƚŚĞƉƌŽĨĞƐƐŝŽŶĂůƐŝŶǀŽůǀĞĚ ? ?
Similarly, report from San Diego ĐŽŵŵĞŶƚƐƚŚĂƚĂ ?debrief for the interdisciplinary group has 
ďĞĞŶĨŽƵŶĚƚŽďĞĞƐƐĞŶƚŝĂů ? ?22 
 
There is an indication then that not only does the potential or actual withdrawal of NIV have a 
significant and extraordinary impact on healthcare professionals, it may also have a direct 
effect on their practice. To achieve best outcomes for patients and their families, the impact on 
professionals and the support they require to avoid adverse effects on their practice needs to 




The aim of this study was to explore, from the perspective of doctors in palliative medicine, the 
issues related to the withdrawal of NIV at the request of a patient with MND and to identify 




A mixed categorical and free text questionnaire was developed using the literature and the 
experience of three consultants in palliative medicine (CF, DO and one other) as a basis for the 
content. The questionnaire was piloted with registrars at one hospice, seeking comment and 
undergoing revision in order to inform reliability and validity. 
 
The opinion of the South East research Ethics Committee was sought and the chair advised that 
NRES ethics approval was not required as the study constituted a service evaluation. 
 
The questionnaire was formatted in Survey Monkey and was sent by email to all doctors who 
were members of the Association of Palliative Medicine of Great Britain and Ireland (993 
doctors). A covering letter outlining the purpose of the study was sent and clearly stated that this 
was s coping exercise form which further research would be informed. No reminder was sent. 
Respondents had 3 months in which to complete the survey. 
 
Participants were asked to rate how practically, emotionally and ethically challenging they found 
the process of NIV withdrawal on an 11 point Likert scale (0=not at all challenging: 10=very 
challenging). They were invited to expand on these three areas using free text. 
 
All responses were anonymised. Free text was thematically analysed using constant comparison 
  
based on grounded theory.29 Text was read by CRH and CF and coded independently. Codes were 
then related to the three major themes (practical, ethical and emotional challenges). Codes were 
subsequently grouped and collapsed as subthemes emerged (CRH). Subthemes and grouping or 




A total of 134 people responded, four of whom were not doctors (one physiotherapist, one 
MND specialist nurse, one clinical nurse specialist in palliative care and one senior nurse). 
Results are reported here for the 130 questionnaires from doctors involved with MND patients. 
Eight (6.2%) of the doctors had not cared for a MND patient who used NIV and a further 46 
(35.4%) had not been involved in the actual withdrawal of NIV at the request of a patient. 
 
Seventy-six (58.5%) respondents had been directly involved in the withdrawal of NIV, 60% had 
under- taken this in the past 12 months but 5% had only  been involved in withdrawal more 
than 5 years before. The majority of respondents (59%) had been involved with more than one 
patient but only 9% had undertaken this in five or more patients in the past 5 years.  
 
The magnitudes of the challenges perceived and experienced by doctors in the practical, ethical 
and emotional dimensions are shown in table 1. A greater percentage of doctors that had not 
been involved in withdrawal of NIV identified that all of these dimensions presented a level of 




Only one respondent (who had never been involved in withdrawal of NIV) felt that practical 
aspects were not at all challenging, but 42% of doctors who had undertaken withdrawal and 
over half of other doctors scored this as 7 or more on the 0 W10 scale. In the absence of 
guidelines, concerns relating to whether or not to wean ventilation, how to manage distressing 
symptoms, the use of sedative drugs (what and how) together with who should remove the 
mask were all issues posed by respondents in free text (Box 1). 
 
There was repeated identification of the huge time and planning burden inherent in this process 
and much focus on the difficulties of communication with patients in terms of timing, sensitivity 
and limitations of such discussions in the face of disease progression and in the absence of any 
prior advance decisions or planning. 
 
 ?dŚĞ ƉƌŽďůĞŵ ŽĨ ĐŽƵƌƐĞ lies with the amount of information given to the patients at 
ĐŽŵŵĞŶĐŝŶŐ  E/s ? We now have large multidisciplinary team meetings involving the 
family and patient if they want to plan the terminal phase and ǁĞĂŶŝŶŐ ? ? 
 
The need for NIV withdrawal to be a multidisciplinary team (MDT) decision was a recurrent 
theme, with many commenting on the inherent challenges faced in terms of the need to support 
all involved, including the patient, family and staff. Managing conflicts that arise from differences 
in opinions within the MDT were also emphasised as practical challenges. 
 
 ?/ ƉĞƌƐŽŶĂůůǇ ĨŝŶĚ ŝƚ ŵŽƐƚ ĐŚĂůůĞŶŐŝŶŐ ǁŚĞŶ ƚŚĞƌĞ ŝƐ ĚŝĨĨŝĐƵůƚǇ ƌĞĂĐŚŝŶŐ ĐŽŶƐĞŶƐƵƐ ǁŝƚŚŝŶ
ƚŚĞĐůŝŶŝĐĂůƚĞĂŵ ? ? 
 
 





³The practical issue of whether sedating before with- drawing is the correct thing to do ? what 
if they die before you withdraw?  The practical issue of whether to wean the NIV or just stop 
ŝƚ ? ? 
 
 ?WƌĂĐƚŝĐĂůůǇ ĐŚĂůůĞŶŐŝŶŐ ĚĞĐŝƐŝŽŶ ŽĨ ǁŚŽ ĂĐƚƵĂůůǇ ƌĞŵŽǀĞƐ the mask, who administers any 
sedative, who judges the correct dose to give and decision whether to give sedation /s ? ? 
 
 ?tŝƚŚ lack of guidance it has been difficult to ensure you are correctly managing the 






Ethical challenges were perhaps seen as less than the practical and emotional challenges but 
were still considerable. 
 
The key themes related to the timing and appropriateness of withdrawal, the need for 
intentions to be clear to all and the time taken to discuss ethical issues with staff (Box 2), and 
the issues related to capacity and ADRTs (Box 3). 
 
While some clearly stated NIV withdrawal is not euthanasia, many acknowledged how they felt 
the process could be construed as causing the death and was potentially open to external 
criticism. The complexity of the ethical stance, that withdrawal of a treatment that is no longer 
requested by the patient is allowing death to occur, rather than causing the death, may not be 
fully appreciated by all involved, even with the healthcare professionals within the team. While 
the ethical logic is understood, the process of NIV withdrawal, for some at least, feels different 
to the withdrawal of other treatments. 
 
 ?/ƚŝƐǁŝƚŚĚƌĂǁŝŶŐĂƚƌĞĂƚŵĞŶƚƚŚĂƚŝƐ ŬĞĞƉŝŶŐƚŚĞŵĂůŝǀĞĂŶĚƐŽŝƚĨĞĞůƐůŝŬĞĞƵƚŚĂŶĂƐŝĂ ? ? 
 
³Ethically ?ŶĞĞĚƚŽďĞĐůĞĂƌĂďŽƵƚĞǀĞƌǇŽŶĞ ?Ɛ ?ǁŝƐŚĞƐĂŶĚŝŶƚĞŶƚŝŽŶƐ ?/ŬŶŽǁŝƚŝƐŶŽƚĚŝĨĨĞƌĞŶƚ
ethically  from not starting a treatment but it feels ĚŝĨĨĞƌĞŶƚ ? ? 
 
 
BOX 2 Ethical issues identified 
 
 ?ƌĞĂƚĞƐƐŝŐŶŝĨŝĐĂŶƚĂŶǆŝĞƚŝĞƐĂŵŽŶŐĨĂŵŝůŝĞƐĂŶĚƐƚĂĨĨwhen a patient requests to withdraw non-
invasive ventilation. Requires a large investment of time to discuss through the ethical issues 
ǁŝƚŚĞĂĐŚŵĞŵďĞƌŽĨƐƚĂĨĨ ? ? 
 
 ?&ĂĐƚŽƌŝŶŐ in the wishes of the patient re timeliness of ǁŝƚŚĚƌĂǁĂů ?  ? being clear about the 
distinction between reaching natural end of life using deep sedation and expediting ĚĞĂƚŚ ? ? 
 
 ? ?/ƚŚŝŶŬ/ŵŝŐŚƚĨŝŶĚƚŚŝƐŵŽƌĞĚŝĨĨŝĐƵůƚ ŝĨ ŝƚǁĂƐďĞŝŶŐƌĞƋƵĞƐƚĞĚĂƚŚŽŵĞĂŶĚŝŶŵǇŵŝŶĚ





BOX 3 Ethical issues relating to mental capacity and the experiences of using advance decision to 
refuse treatment (ADRT) 
 
 ? ?ŝŶƚŚĞĐŽŶƚĞǆƚŽĨĨĂŝůŝŶŐĐŽŵŵƵŶŝĐĂƚŝŽŶ  ?A? ?ALĐŽŐŶŝƚŝŽŶ ? ? it is hard to be confident in respecting   
autonomy, and where capacity has been lost it is hard to be confident where best interests lie, 
and either way there are often conflicts which can further undermine ĐŽŶĨŝĚĞŶĐĞ ? ?
 
  ?KŶĞ of the ethical challenges rests in interpreting ƉƌĞǀŝŽƵƐůǇĞǆƉƌĞƐƐĞĚǁŝƐŚĞƐ ?/ŚĂǀĞfound 
that even (seemingly) well thought out ADRT that have been extensively discussed with the 






While two respondents (one who had withdrawn NIV and one who had not) were not at all 
challenged emotionally by the process, over half of respondents scored this as 7 or more and 
20% as 9 or 10 on the 0 W10 scale. 
 
The emotional burden which was felt in terms of managing the emotions of others (patient, 
family and staff) throughout the process was the commonest theme to emerge. Supporting 
others and conflict resolution formed part of this burden (Box 4). 
 
Concerns about causing harm or distress to the patient were also common. But perhaps the most 
complex emotional issue was related to death being so related to an action, albeit not the 
intention of the action (Box 5). 
 
 
BOX 4 Emotional challenges for doctors in withdrawing non-invasive ventilation (NIV) 
 
 ?/ found dealing with the (very highly expressed) emotions of staff watching, assisting or aware 
of the withdrawal of NIV in a patient was more challenging for me than the emotions of the 
ĨĂŵŝůǇ ? ? 
 
 ?'ƌĞĂƚĞƐƚ stress is in dealing with the families rather than the patient (and sometimes with 
members of the wider clinical ƚĞĂŵ ? ? ? 
 
 
BOX 5 Emotional impact of the consequences of action 
 
͞ůƚŚŽƵgh very clear as to the morals and ethics of the situation, the emotional drain was 
enormous as we are so unused to having that much control over the timing and place of 
ĚĞĂƚŚ ? ? 
 
 ?/ĚŽ ĨŝŶĚƚŚĞƌĂƉŝĚƚƌĂŶƐŝƚŝŽŶ ĨƌŽŵ ůŝǀŝŶŐƚŽĚǇŝŶŐĂŝĚĞĚ by the removal of a life sustaining 
treatment and supported by respiratory and conscious level depressant drugs to be more 
ƐƚƌĞƐƐĨƵůƚŚĂŶŵŽƐƚŽƚŚĞƌĂƌĞĂƐŽĨƉƌĂĐƚŝĐĞ ? ? 
 
 ?/ƚĨĞĞůƐůŝŬĞ/ĂŵĐĂƵƐŝŶŐƚŚĞŝƌĚĞĂƚŚĞǀĞŶƚŚŽƵŐŚ/ĂŵĐĂƌƌǇŝŶŐŽƵƚƚŚĞŝƌǁŝƐŚĞƐĂŶĚŝƚŝƐŝŶ
fact a horrible disease that is killing them. My rational brain can eventually navigate the 





Discussion and conclusions 
 
This survey has identified that there are considerable challenges faced by those palliative 
medicine doctors involved in the withdrawal of NIV at the request of a patient with MND. It 
appears that compared with those doctors who have actually been involved in withdrawal of NIV, 
a greater percentage of doctors  that had not been involved in withdrawal of NIV identify that 
each of the practical, ethical and emotional dimensions present a level of challenge of 7 or more 
to them. This could mean that experience some- what overcomes the challenge of the situation. 
The perceived challenges, despite experience however, remain great. Clinical and team leadership 
is challenged by the rarity of the event, the lack of evidence base and guidance to draw on, and 
the emotional impact on the doctor themselves. Perhaps another impact of the rarity is that in 
addition, there are few colleagues to approach who can ĂĚǀŝƐĞĂŶĚŵĞŶƚŽƌ ?ŶŽǀŝĐĞƐ ? ?
 
There is a clear desire that discussions with patients with MND and their families concerning the 
benefits and challenges of using NIV and the choices that some will face need to be better 
integrated into care at earlier stages of the disease. There is little detailed published information 
about what happens to patients using NIV as they deteriorate and die, thus making informed 
consent and general sharing of information with patient and families difficult.12 Better  
development of advance care planning (ACP) processes is crucial. However, although many 
patients with MND can fully engage in ACP and novel methods can facilitate this, the reality with 
some patients and their families is that conversations about future deterioration and the grief of 
loss are overwhelming, avoided or traumatic. Avoidance may be from the patient, family and 
ƉƌŽĨĞƐƐŝŽŶĂůƐ ?dŚƵƐĐůĂƌŝƚǇĂďŽƵƚĂĚǀĂŶĐĞǁŝƐŚĞƐ ?ƵŶĚĞƌǁŚĂƚĐŝƌĐƵŵƐƚĂŶĐĞƐǁŽƵůĚǇŽƵǁŝƐŚƚŽ
ŶŽůŽŶŐĞƌĐŽŶƚŝŶƵĞE/s ? ?can sometimes be very difficult. For others, choice preference is 
 ?ƵŶƐƚĂďůĞ ?ĂŶĚĐĂŶůĞĂĚƚŽĂĐĐĞƉƚĂŶĐĞŽƌƌĞũĞĐƚŝŽŶŽĨƚƌĞĂƚŵĞŶƚƐƚŚŽƵŐŚƚƵŶůŝŬĞůǇƚŽďĞǁĂŶƚĞĚ
when planning hypo- thetically.30 This case has resonance to the findings of the SUPPORT (Study 
to Understand Prognoses and Preferences for Outcomes and Risks of Treatment) study which 
found that outcomes often did not match preferences stated in advance of the clinical need.31 In 
general, ACP does seem to help patients who maintain capacity, to be able to engage better in 
decision  making when the time comes, and reduces the distress of relatives if best interest 
decisions need to be made when the patient loses capacity.32 The outcomes of ACP, specifically in 
patients with MND, are yet to be explored. 
 
 
The ethical context is well rehearsed 
 
The right of a patient with capacity who requests withdrawal of a medical treatment must, in 
most countries including the UK, be respected and the treatment stopped.13 14 25 33 34 To continue 
a medical treatment which the patient has said they do not want is, in most countries, illegal. The 
challenges to this black and white ethical principle in real world clinical practice are multifactorial 
ĂŶĚŝŶĐůƵĚĞ P ?ŝƚŵĂǇďĞƚŚĂƚƚŚĞƉĂƚŝĞŶƚǁĂŶƚƐƚŽƐƚŽƉĂŶĚƚŚĂƚƌĞƋƵĞƐƚŵƵƐƚďĞƌĞƐƉĞĐƚĞĚ ?ďƵƚ
ŐŝǀĞŶƚŚĂƚƚŚĞǇŵĂǇŶĞĞĚĂƐƐŝƐƚĂŶĐĞŝŶƐƚŽƉƉŝŶŐ ?ƚŚĞǇĐĂŶ ?ƚŵŽǀĞƚŚĞŝƌŚĂŶĚƐ to remove the 
mask] and want to avoid suffering [so need drugs for symptom management] does it have to be 
ŵĞ ?ŵǇƐĞƌǀŝĐĞƚŚĂƚĚŽĞƐƚŚŝƐ ? ?24 Like the respondents to our much larger survey, authors 
describe considerable time, effort and emotional energy that is needed to discuss the decision 
with the patient and their family, and to gain understanding and agreement in the MDT about the 
withdrawal rationale. 
 
The emotional challenges appear more complex and require further investigation. The ethical 
  
literature emphasises the stressful nature of this area of clinical care and how differences in 
opinion and ďĞůŝĞĨ ?ĚĞƐƉŝƚĞĂƵŶŝĨŽƌŵůĞŐĂůĐŽŶƚĞǆƚ ?ĐĂŶŝŶĨůƵĞŶĐĞĂĚŽĐƚŽƌ ?ƐƉƌĂĐƚŝĐĞĂŶĚůĞǀĞů
of distress. In our survey, many respondents reported a cognitive Wemotional dissonance for 
themselves, and many described having to manage their own unusual emotions. The emotional 
burden is compounded for some by the need to both support the team and sometimes 
shoulder antagonism from team members, echoing findings in smaller studies.21 35 
 
Healthcare professionals working in palliative medicine were chosen as the sample population 
for this scoping survey purposefully with the understanding that those working in different 
specialities involved in withdrawal of NIV in MND (eg, respiratory or neurology specialities) may 
have additional insights to add. About 13% of the APM membership responded to the survey. As 
the survey was electronic, it is not posƐŝďůĞƚŽŬŶŽǁƚŚĞŶƵŵďĞƌǁŚŽĂĐƚƵĂůůǇ ?ŽƉĞŶĞĚ ?ƚŚĞ
survey. The survey will have had relevance only to doctors who care for patients with MND, 
which will include an unknown percentage of members of the APM. The response rate is thus 
not possible to calculate. Those that responded to the survey might however be those that have 
experienced more challenges compared with those that did not respond. Even so, these 
findings are from a sizeable group of doctors in palliative medicine in the UK. 
 
While this survey goes well beyond any other literature, it is still a very superficial exploration of 
this area of practice which is worthy of deeper exploration. Why is it, as one respondent put it, 
that withdrawal of NIV at the request of a patient with MND  ?ŝŶtheory, ethically, legally and 
practically should be straightforward, ŝŶƌĞĂůŝƚǇŝƐĂďƐŽůƵƚĞůǇŶŽƚ ? ?Moreover, how can we 
mitigate the challenges to best outcomes for all concerned? Consideration of targeted support 
for MDT members involved in withdrawal of NIV, including education, psychological support and 
debriefing sessions, may all be valuable.36 Withdrawal of NIV from a patient who, without it, will 
experience severe symptoms of breathless and feelings of suffocation requires careful planning. 
The when, where, who and how need to be discussed, planned and documented in detail. The 
results of our survey suggest that at least in part, practical challenges could be addressed by 
development of guidelines on NIV withdrawal for patients with MND. Ethical challenges could 
be alleviated by incorporating a clear ethical statement within this guideline. We suggest also 




What is already known on this subject 
 
x There is little current evidence looking at the issues faced by healthcare professionals 
involved in the withdrawal of non-invasive ventilation at the request of patients with 
motor neurone disease. 
x Some case reports identify this as an area of considerable complexity which may cause 
controversy within the healthcare team 
 
 
What this study adds 
 
x There is little current evidence looking at the issues faced by healthcare professionals 
involved in the withdrawal of non-invasive ventilation at the request of patients with 
motor neurone disease. 
x Some case reports identify this as an area of considerable complexity which may cause 


















The authors would like to thank the participants for their honesty and responsiveness, and 
Sabine Tuck, at the Association for Palliative Medicine of Great Britain and Ireland, for her 
administration of the survey. 
 
Contributors   
CRH, DO and CF devised the questionnaire,  CRH led the analysis of the results and DO and 
CF contributed to this. CF led the writing of the paper; both CRH and DO have commented 
on drafts and agreed the final content. 
 
Funding  
LOROS funded the time for CF and CRH. DO funded the cost of administration of the 
questionnaire, and Wisdom Hospice funded the time of DO. 
 
Ethics approval  
The opinion of the South East Research Ethics Committee was sought and the chair advised 
that NRES ethics approval was not required as the study constituted a service evaluation. 
 
Competing interests 
 DO was a member of the guideline development group for the NICE clinical guideline on NIV 
in MND Guideline 105.3 
 
Data sharing statement  
The paper includes a summary of quantitative and qualitative findings. All raw data are 



























1 Bourke SC, Tomlinson M, Williams TL, et al. Effects of non-invasive ventilation on 
survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised 
controlled trial. Lancet Neurol 2006;5:140 W7. 
 
2 Piepers S, van den Berg JP, Kalmijn S, et al. Effect of non-invasive ventilation on survival, 
quality of life, respiratory function and cognition: a review of the literature. Amyotroph 
Lateral Scler 2006;7:195 W200.  
 
 
3 NICE Clinical Guideline 105: Motor neurone disease; the use of non-invasive ventilation in 
the management of motor neurone disease. NICE, 2010. 
 
4 Lemoignan J, Ellis C. Amyotrophic lateral sclerosis and assisted ventilation: how patients 
decide. Palliat Support Care 2010;8:207 W13. 
 
5 Oliver D, Faull C. Non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone 
disease. Minerva Pneumologica 2013;52:27 W38. 
6 Lyall RA, Donaldson N, Fleming T, et al. A prospective study of quality of life in ALS 
patients treated with non-invasive ventilation. Neurology 2001;57:153 W6. 
 
7 Young :D ?DĂƌƐŚĂůů> ?ŶĚĞƌƐŽŶ: ?ŵǇŽƚƌŽƉŚŝĐůĂƚĞƌĂůƐĐůĞƌŽƐŝƐƉĂƚŝĞŶƚƐ ?ƉĞƌƐƉĞĐƚŝǀĞƐ
on the use of mechanical ventilation. Health Soc Work 1994;19:253 W60. 
 
8 Ganzini L, Johnston W, Silveira M. The final month of life in patients with ALS. 
Neurology 2002;59:428 W31. 
 
9 Oliver D. Ventilation in motor neuron disease: difficult decisions in difficult 
circumstances. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:6 W8. 
 
10 Mental Capacity Act. 2005. http://www.legislation.gov.uk/ ukpga/2005/9/contents 
(accessed 29 Jan 2013). 
 
11 Moss AH, Oppenheimer EA, Casey P, et al. Advance care planning and outcomes receiving 





12 tŚŝƚĞŚĞĂĚ ?K ?ƌŝĞŶD ?:ĂĐŬ ?et al. Experiences of dying, death and bereavement in 
motor neurone disease: a qualitative study. Palliat Med 2011;26:368 W78. 
 
13 Polkey MI, Lyall RA, Davidson AC, et al. Ethical and clinical issues in the use of home non-
invasive mechanical ventilation for the palliation of breathlessness in motor neurone 
disease. Thorax 1999;54:367 W71. 
 
14 Borasio GD, Voltz R. Discontinuation of mechanical ventilation in patients with 
amyotrophic lateral sclerosis. J Neurol 1998;245:717 W22. 
 
15 Heffernan C, Jenkinson C, Holmes T, et al. Management of respiration in MND/ALS 
patients; an evidence based review. Amyotroph Lateral Scler 2006;7:5 W15. 
 
16 Dreyer PS, Felding M, Klitnaes CS,  et  al.  Withdrawal  of invasive home mechanical 
ventilation in patients with advanced amyotrophic lateral sclerosis: ten years of Danish 
experience.J Palliat Med 2012;15:205 W9. 
 
17 Eng D. Management guidelines for motor neurone disease patients on non invasive 
ventilation at home. Palliat Med 2006;20:69 W79. 
 
18 Andersen PM, Abrahams S, Borasio GD, et al. The EFNS task force on diagnosis and 
management of amyotrophic lateral sclerosis. EFNS guidelines on the clinical 
management of amyotrophic lateral sclerosis (MALS) ? a revised report of an EFNS task 
force. Eur J Neurol 2012;19:360 W75. 
 
19 von Gunten C, Weissman DE. Ventilator withdrawal protocol. J Palliat Med 2003;6:773 W4. 
 
 
20 von Gunten C, Weissman DE. Symptom control for ventilator withdrawal in the dying 
patient. J Palliat Med 2003;6:774 W5. 
 
21 Clinch A, Le B. Withdrawal of mechanical ventilation in the home: a case report and 
review of the literature. Palliat Med 2011;25:378 W81. 
 
22 Oppenheim S, Bos C, Heim P, et al. Developing guidelines for life support therapy 
withdrawal in the home. J Palliat Med 2010;13:491 W2. 
 
23 British Broadcasting Corporation. Inside the ethics committee: withdrawing treatment. 
2011. http://www.bbc.co.uk/ programmes/b012r7jn (accessed 29 Jan 2013). 
 
24 Gannon C. A request for hospice admission from hospital to withdraw ventilation. J Med 
Ethics 2005;31:383 W4. 
 
25 Goldblatt D, Greenlaw J. Starting and stopping the ventilator for patients with 
amyotrophic lateral sclerosis. Neurol Clin 1989;7:789 W805. 
 
  
26 Rubenfeld GD. Withdrawing life sustaining treatment in the intensive care unit. 
Respir Care 2000;45: 1399 W407. 
 
27 Christakis N, Asch D. Biases in how physicians choose to withdraw life support. Lancet 
1993;342:642 W6. 
 
28 Guidelines for withdrawing non-invasive ventilation in patients with NIV. Leicestershire and 
Rutland MND  Supportive palliative care group. Nov 2009. http://www.leicestershospitals. 
nhs.uk/aboutus/departments-services/neurology/ 
motor-neurone-disease/professional-information/ (accessed 29 Jan 2013). 
 
29 Strauss A, Corbin J. Basics of qualitative research: grounded theory procedures and 
techniques. London: Sage, 1990. 
 
30 Berger JT. Preemptive use of palliative sedation and amyotrophic lateral sclerosis. J Pain 
Symptom Manage 2012;43:802 W5. 
 
31 Teno J, Lynn J, Wenger N,  et  al.  Advance directives  for seriously ill hospitalized patients: 
effectiveness with the patient self-determination act and the SUPPORT intervention. 
SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and 
Risks of Treatment. J Am Geriatr Soc 1997;45:500 W7. 
 
32 Wong R. Advance care planning. In: Faull C, De Caestecker S, Nicholson A, et al. eds. 
Handbook of palliative care. 3rd edn. Oxford: Wiley-Blackwell, 2012:93 W108. 
 
33 McCluskey L, Elman L. End of life care: ethical issues. In: Oliver D, Borasio G, Walsh D, 
eds. Palliative care in amyotrophic lateral sclerosis ? from diagnosis to bereavement. 2nd 
edn. Oxford: Oxford University Press, 2006:265 W85. 
34 Truog RD, Burns JP. To breathe or not to breathe. J Clin Ethics 1994;5:39 W41. 
 
35 Le Bon B, Fisher S. Case report: Maintaining and withdrawing long-term invasive 
ventilation in a patient with MND/ALS in a home setting. Palliat Med 2011;25:262 W5. 
 
36 Gallagher D, Monroe B. Psychosocial care. In: Oliver D, Borasio G, Walsh D, eds. Palliative 
care in amyotrophic lateral sclerosis ? from diagnosis to bereavement. 2nd edn. Oxford: 































 Table 1  
Level of practical, emotional and ethical challenges identified by respondents who had and 





                      Score 0-3           Score 4-6             Score 7+ 
 
 
Those doctors with direct  
experience of withdrawal of NIV (n (%)) 
 
 
   Practical challenge  17 (22)  27 (36)  32 (42) 
 
   Ethical Challenge  26 (34)  35 (33)  25 (33) 
 
   Emotional challenge  13 (17)  26 (34)  37 (49) 
 
 
Those doctors involved with  
MND patients with NIV but no direct  
experience of withdrawal of NIV (n (%)) 
 
   Practical challenge  5 (14)  10 (29)  20 (57) 
 
   Ethical Challenge  10 (29)  10 (29)  15 (43) 
 




MND, motor neurone disease; NIV, non-invasive ventilation 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
